Merck Fires on All Cylinders in Q3 With Soaring Sales for Keytruda
Claiming a powerful immunotherapy that's on track to become the biggest-selling drug in the world doesn't guarantee that everything will go right for a stock. Merck's (NYSE: MRK) Keytruda will almost certainly soon hold the No. 1 best-seller status, but the big pharma stock hasn't even been able to keep up with the S&P 500 index so far this year.
Merck announced its third-quarter results before the market opened on Tuesday. Thanks largely to Keytruda, the company made investors happy with those results. Here are the highlights from Merck's Q3 update.
Image source: Getty Images.
Source Fool.com
